Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
02/2005
02/23/2005CN1585744A Process for the preparation of benazepril
02/23/2005CN1585645A Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
02/23/2005CN1585642A Pharmaceutical compositions containing 3, 4-propinoperhydropurines and uses thereof for blocking neuronal transmission
02/22/2005US6858233 Simmondsin processing methods and products
02/22/2005US6858232 Topical transdermal treatments
02/22/2005CA2129039C Tri-substituted phenyl derivatives as phosphodiesterase inhibitors
02/17/2005WO2005013920A2 Newcastle disease virus administration
02/17/2005WO2005013919A2 Treatment using dantrolene
02/17/2005WO2005013918A2 Compositions, methods and kits relating to poxvirus subunit vaccines
02/17/2005WO2005013917A2 Combination therapy for treating alphavirus infection and liver fibrosis
02/17/2005WO2005013915A2 Novel indications for transforming growth factor-beta regulators
02/17/2005WO2005013913A2 Peroxygen containing particle in an alcohol containing gel
02/17/2005WO2005013912A2 Anti-fcrn antibodies for treatment of auto/allo immune conditions
02/17/2005WO2005013911A2 Protective and therapeutic uses for tocotrienols
02/17/2005WO2005013910A2 Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
02/17/2005WO2005013909A2 Novel cathepsin k inhibitors
02/17/2005WO2005013908A2 Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
02/17/2005WO2005013907A2 Pyrrolo[1,2-b]pyridazine derivatives
02/17/2005WO2005013906A2 pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT
02/17/2005WO2005013905A2 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
02/17/2005WO2005013904A2 Sars nucleic acids, proteins, vaccines, and uses thereof
02/17/2005WO2005013903A2 Derivatives of substituted quinone and uses thereof
02/17/2005WO2005013902A2 Methods and compositions for inhibiting the proliferation of prostate cancer cells
02/17/2005WO2005013901A2 Oligomeric compounds and compositions for use in modulation of small non-coding rnas
02/17/2005WO2005013899A2 Compositions and methods for the therapy and diagnosis of lung cancer
02/17/2005WO2005013898A2 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
02/17/2005WO2005013896A2 Programmed immune responses using a vaccination node
02/17/2005WO2005013895A2 Compositions and methods for the treatment of schizophrenia and addictive disorders
02/17/2005WO2005013894A2 Benzodiazepine cgrp receptor antagonists
02/17/2005WO2005013893A2 Cancer related genes
02/17/2005WO2005013892A2 Hydrolytically-resistant boron-containing therapeutics and methods of use
02/17/2005WO2005013890A2 Function and regulation of angiopoietin-3/angiopoietin-4
02/17/2005WO2005013889A2 Truncated fragments of alpha-synuclein in lewy body disease
02/17/2005WO2005013888A2 Compounds, compositions and methods
02/17/2005WO2005013886A2 Methods for treating and preventing apoptosis-related diseases using rna interfering agents
02/17/2005WO2005013885A2 Pharmaceutical compositions and methods for accelerating wound healing
02/17/2005WO2005013884A2 Methods for preventing neurological events
02/17/2005WO2004110344A3 New azetidine compounds
02/17/2005WO2004108884A3 Composite materials and particles
02/17/2005WO2004108068A3 4-[4-(4-morpholino)anilino]pyrimidine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
02/17/2005WO2004103264A3 Hemostatic antibacterial composition and products incorporating the same
02/17/2005WO2004093829A3 (-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2
02/17/2005WO2004093781A3 Podophyllotoxin derivatives as igf-1r inhibitors
02/17/2005WO2004091551A3 Anti-tumor vasculature effects of human serum albumin derivatives
02/17/2005WO2004091483A3 Once daily formulations of tetracyclines
02/17/2005WO2004089278A3 Sexual hygienic composition
02/17/2005WO2004087044A3 Drug target
02/17/2005WO2004084813A3 Chemical compounds
02/17/2005WO2004080391A3 Novel antibacterial agents
02/17/2005WO2004078114A3 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
02/17/2005WO2004075860A3 Process for purification of zoledronic acid
02/17/2005WO2004071423A3 Methods of administering opioid antagonists and compositions thereof
02/17/2005WO2004043345A3 Extract of trapa natans and methods of using the same
02/17/2005WO2003101396A3 Helper virus-free herpesvirus amplicon particles and uses thereof
02/17/2005US20050038251 Process for manufacturing opioid analgesics
02/17/2005US20050038124 Highly pure modafinil
02/17/2005US20050038109 treatment of solid tumor cancers
02/17/2005US20050038098 Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
02/17/2005US20050038070 Tetrahydroquinoline derivatives; modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer
02/17/2005US20050038067 A compound with azo containing mono and a bicyclic rings attached with an aryl or heteroaryl ring; both therapeutic and diagnostic
02/17/2005US20050038054 Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
02/17/2005US20050038049 Prevention, therapy of disease sensitivie to kinase; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis; psychological disorders; schizophrenia
02/17/2005US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
02/17/2005US20050038009 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- alpha -[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine
02/17/2005US20050038004 Synergistic mixture of steroid and anticholinergic agent; respiratory system disorders
02/17/2005US20050037996 Controlling temperature and pH while complexing
02/17/2005US20050037992 Composition and method for treating neurological disorders
02/17/2005US20050037979 Tannate compositions and methods of use
02/17/2005US20050037947 Bioavailability; controlling dosage ; chimera protein coupling to immunoglobulin
02/17/2005US20050037439 Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
02/17/2005US20050037376 Sulfatase polypeptide for use in treatment and prevention of microbial infection, cell proliferative, neurodegenerative and cardiovascular disorders
02/17/2005US20050037369 Using cell surface and lymphocyte receptors to identify modulator for use in treatment and prevention of graft rejection and cell proliferative disorders; peptide mimetics; imaging diagnostics
02/17/2005US20050037101 Preventative effects of morinda citrifolia on mammary breast cancer
02/17/2005US20050037091 Composition comprising paracetamol and a bitterness masking component
02/17/2005US20050037088 Process of making flowable hemostatic compositions and devices containing such compositions
02/17/2005US20050037075 Targeted delivery of controlled release polymer systems
02/17/2005US20050037070 Acid labile proton pump inhibitor microencapsulated with material that enhances shelf-life of pharmaceutical formulation, and antacid, wherein initial serum concentration of proton pump inhibitor is greater than 0.1 mu g/ml at any time within 30 minutes after administration of pharmaceutical; shelf life
02/17/2005US20050037054 Gloves containing dry powdered Aloe and method of manufacturing
02/17/2005US20050037032 Composition and method of treatment for urogenital conditions
02/17/2005US20050037014 T helper cell epitopes
02/17/2005US20050036992 Novel use of liver X receptor agonists
02/17/2005US20050036984 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
02/17/2005US20050036964 Makeup compositions for dark skins
02/17/2005US20050036951 Methods of treating lung diseases
02/17/2005US20050034652 Crystalline forms of modafinil
02/17/2005CA2537865A1 Neuroprotectin protects against cellular apoptosis, neuronal stroke damage, alzheimer's disease and retinal degeneration
02/17/2005CA2537555A1 Compositions and methods for the therapy and diagnosis of lung cancer
02/17/2005CA2535446A1 Methods for preventing neurological events
02/17/2005CA2535029A1 Pharmaceutical compositions and methods for accelerating wound healing
02/17/2005CA2534973A1 Anti-fcrn antibodies for treatment of auto/allo immune conditions
02/17/2005CA2532795A1 Sense antiviral compound and method for treating ssrna viral infection
02/17/2005CA2531032A1 Programmed immune responses using a vaccination node
02/17/2005CA2529792A1 Hydrolytically-resistant boron-containing therapeutics and methods of use
02/17/2005CA2529196A1 Benzodiazepine cgrp receptor antagonists
02/17/2005CA2526900A1 Truncated fragments of alpha-synuclein in lewy body disease
02/17/2005CA2519294A1 Newcastle disease virus administration
02/16/2005EP1506185A1 Novel compounds and their use
02/16/2005EP1506178A2 Bicyclic modulators of androgen receptor function
02/16/2005EP1506006A2 Improved combined vaccine against mycoplasma hyopneumoniae and porcine viruses
02/16/2005EP1505991A1 A drugs association against influenza virus
1 ... 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 ... 295